Clinically, PPARγ agonists Such as TZDs Like pioglitazone and rosiglitazone are used to treat type 2 diabetes, while PPARα agonists like fibrates target hyperlipidemia and cardiovascular risks [55]. This evidence concerns the gene PPARG and type 2 diabetes mellitus.